Fezolinetant

(Veozah)

Fezolinetant

Drug updated on 11/17/2023

Dosage FormTablet (oral: 45 mg)
Drug ClassNeurokinin 3 (NK3) receptor antagonist
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.